EUVIMEDEUVIMED entdecken
Vergleichsstudie

Risk of Cancer Comparing Warfarin and Direct Oral Anticoagulants: Population-Based Cohort Studies in England and Hong Kong

Zixuan Wang, Qiuyan Yu, Julian Matthewman, John Tazare, Sara Benitez Majano, Jeremy Brown, Ka Shing Cheung, Celine S L Chui, Esther W Y Chan, Krishnan Bhaskaran, Ian C K Wong, Ian J Douglas und 1 weitere

Drug Safety · 2026

DOI: 10.1007/s40264-025-01645-3 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Drug Safety, 2026. Verfasst von Zixuan Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Non-Communicable Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, K…. Hauptthemen laut MEDLINE: Warfarin, Anticoagulants, Neoplasms, Atrial Fibrillation. Die Arbeit nennt 32 Literaturangaben. Gefördert von: Laboratory of Data Discovery for Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Previous evidence suggests a potential protective effect of warfarin against cancer, compared to non-users. However, it may be prone to immortal time bias and residual confounding. OBJECTIVE: We aimed to examine the association between cancer and warfarin, compared with active comparator (direct oral anticoagulants). METHODS: We conducted studies using population-based databases from England and Hong Kong to investigate the association between warfarin and hazard of cancer using a new-user active-comparator cohort design. People with atrial fibrillation aged ≥ 18 years who had first received anticoagulant treatment during 01/01/2011-31/12/2019 were involved. RESULTS: No evidence supported the association between warfarin and hazard of overall cancer, compared with direct oral anticoagulants in both settings (England: hazard ratio [HR] = 1.03, 95% confidence interval [CI] 0.94-1.13; Hong Kong: HR = 0.89, 95% CI 0.79-1.01). A lower hazard of female breast (HR = 0.49, 95% CI 0.30-0.79), ovarian (HR = 0.07, 95% CI 0.01-0.58), and pancreatic (HR = 0.46, 95% CI 0.22-0.96) cancers and a higher hazard of kidney cancer (HR = 3.57, 95% CI 1.64-7.76) were found in Hong Kong, comparing warfarin with direct oral anticoagulants, but these were not replicated in England. CONCLUSIONS: This study does not find a protective effect of warfarin against cancer versus direct oral anticoagulants. The risks of site-specific cancers including pancreatic, kidney, and sex-specific cancers between oral anticoagulants shown in the Hong Kong setting only may require further investigation in other independent datasets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

WarfarinAnticoagulantsNeoplasmsAtrial FibrillationHumansHong KongFemaleEnglandMaleCohort StudiesAdministration, OralAgedMiddle AgedRisk FactorsAged, 80 and over

Substanzen

WarfarinAnticoagulants

Autor:innen und Institutionen

  • Department of Non-Communicable Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel St, London, WC1E 7HT, UK.
  • Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, Hong Kong, China.
  • School of Pharmacy, School of Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK.
  • Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong, China.
  • Department of Medical Statistics, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.
  • Department of Medicine, School of Clinical Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.

Förderung

  • Laboratory of Data Discovery for Health

Zitieren

APA

Wang, Z., Yu, Q., Matthewman, J., Tazare, J., Majano, S. B., Brown, J., Cheung, K. S., Chui, C. S. L., Chan, E. W. Y., Bhaskaran, K., Wong, I. C. K., Douglas, I. J., & Wong, A. Y. S. (2026). Risk of Cancer Comparing Warfarin and Direct Oral Anticoagulants: Population-Based Cohort Studies in England and Hong Kong. Drug Safety. https://doi.org/10.1007/s40264-025-01645-3

Vancouver

Wang Z, Yu Q, Matthewman J, Tazare J, Majano SB, Brown J, et al. Risk of Cancer Comparing Warfarin and Direct Oral Anticoagulants: Population-Based Cohort Studies in England and Hong Kong. Drug Safety. 2026. doi:10.1007/s40264-025-01645-3

BibTeX
@article{Wang2026,
  author = {Wang, Zixuan and Yu, Qiuyan and Matthewman, Julian and Tazare, John and Majano, Sara Benitez and Brown, Jeremy and Cheung, Ka Shing and Chui, Celine S L and Chan, Esther W Y and Bhaskaran, Krishnan and Wong, Ian C K and Douglas, Ian J and Wong, Angel Y S},
  title = {Risk of Cancer Comparing Warfarin and Direct Oral Anticoagulants: Population-Based Cohort Studies in England and Hong Kong},
  journal = {Drug Safety},
  year = {2026},
  doi = {10.1007/s40264-025-01645-3}
}
Kostenlos starten →